Nombre del producto:4-(Chlorodifluoromethoxy)aniline

IUPAC Name:4-(chlorodifluoromethoxy)aniline

CAS:39065-95-7
Fórmula molecular:C7H6ClF2NO
Pureza:95%+
Número de catálogo:CM252669
Peso molecular:193.58

Unidad de embalaje Stock disponible Precio($) Cantidad
CM252669-1000g in stock ƋɐȷȌ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :39065-95-7
Fórmula molecular:C7H6ClF2NO
Punto de fusión:-
Código de sonrisas:NC1=CC=C(OC(F)(Cl)F)C=C1
Densidad:
Número de catálogo:CM252669
Peso molecular:193.58
Punto de ebullición:231.9°C at 760 mmHg
Nº Mdl:MFCD01820809
Almacenamiento:Keep in dark place, store at 2-8°C.

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Asciminib
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.